专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP3234196A1 ID4 PROTEIN RESTORES WILD TYPE P53 ACTIVITY 审中-公开
标题翻译： ID4蛋白复性野生型P53活性
公开(公告)号：EP3234196A1
公开(公告)日：2017-10-25
申请号：EP15870913.9
申请日：2015-12-15
申请人： Clark Atlanta University
发明人： CHAUDHARY, Jaideep , PATEL, Divya , KNOWELL, Ashley, E.
IPC分类号： C12Q1/68 , G01N33/53
CPC分类号： A61K38/1709 , C07K14/4705 , C07K14/4746
摘要： A compound and method for treating cancer, in particular prostate cancer. Id4 reverts mutant p53 activity to its wild type physiological status and activity. Id4 or its peptidemimatics are used to revert mutant p53 to wild type p53, restoring its tumor suppressor activity.
摘要翻译：治疗癌症，特别是前列腺癌的化合物和方法。 Id4将突变型p53活性恢复至其野生型生理状态和活性。使用Id4或其多肽微生物将突变型p53恢复至野生型p53，恢复其肿瘤抑制活性。

2. 发明公开

EP3118218A3 FUSION PROTEINS FOR BLOOD-BRAIN BARRIER DELIVERY 审中-公开
标题翻译：用于血脑屏障递送的融合蛋白
公开(公告)号：EP3118218A3
公开(公告)日：2017-03-15
申请号：EP16171496.9
申请日：2006-09-28
申请人： ArmaGen Technologies, Inc.
发明人： PARDRIDGE, William , BOADO, Ruben
IPC分类号： C07K14/475 , C07K16/28 , A61K38/18 , A61P25/00
CPC分类号： C07K16/2869 , A61K2039/505 , C07K14/475 , C07K2317/24 , C07K2319/00 , C07K2319/30
摘要： The invention provides compositions, methods, and kits for increasing transport of agents across the blood brain barrier while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems. In some embodiments the agents are therapeutic, diagnostic, or research agents.
摘要翻译：本发明提供了组合物，方法和试剂盒，用于增加试剂穿过血脑屏障的运输，同时允许它们一旦穿过屏障时的活性基本保持完整。药物通过一种或多种内源性受体介导的运输系统运输穿过血脑屏障。在一些实施方案中，药剂是治疗剂，诊断剂或研究药剂。

3. 发明公开

EP3356833A1 ANTIBODIES THAT BIND HUMAN CANNABINOID 1 (CB1) RECEPTOR 审中-公开
公开(公告)号：EP3356833A1
公开(公告)日：2018-08-08
申请号：EP16852398.3
申请日：2016-09-27
申请人： BIRD ROCK BIO, INC.
发明人： KRETZ-ROMMEL, Anke , FERRINI, Roger
IPC分类号： G01N33/94 , G01N33/543
CPC分类号： C07K16/28 , A61K47/6849 , C07K16/32 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/6872 , G01N2333/726
摘要： The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.

4. 发明公开

EP3338092A1 METHOD OF ESTIMATING THE INCIDENCE OF IN VIVO REACTIONS TO CHEMICAL OR BIOLOGICAL AGENTS USING IN VITRO EXPERIMENTS 审中-公开
公开(公告)号：EP3338092A1
公开(公告)日：2018-06-27
申请号：EP16837831.3
申请日：2016-08-18
申请人： Coyne Scientific, LLC
发明人： COYNE, Kevin P. , COYNE, Shawn T. , NGUYEN, PH.D., Anh
IPC分类号： G01N33/50
CPC分类号： G01N33/5014 , G01N2800/52 , G06F19/24 , G16H50/70
摘要： A method is provided for estimating or predicting, a priori, the incidence or degree of biological reaction by an individual in a population of interest when exposed to a chemical or biological agent of interest in vivo. The method uses a combination of data from in vitro experiments using the agent of interest, from in vitro experiments using a reference agent, and data obtained regarding the incidence or degree of the in vivo effects of the reference agent.

5. 发明公开

EP3302430A1 LIQUID FORMULATIONS OF CELECOXIB FOR ORAL ADMINISTRATION 审中-公开
标题翻译：口服给药用塞来考布液体制剂
公开(公告)号：EP3302430A1
公开(公告)日：2018-04-11
申请号：EP16804009.5
申请日：2016-05-24
申请人： Kiel Laboratories, Inc.
发明人： KIEL, Jeffrey, Scott , BRYANT, Thomas, Jeffrey , LEVASSEUR, Richard, Gerard , THOMAS, Hugh, Greg
IPC分类号： A61K9/08 , A61K31/415 , A61K47/10 , A61K47/30 , C07D231/12
CPC分类号： A61K31/635 , A61K9/0095 , A61K9/08 , A61K9/10 , A61K47/02 , A61K47/10 , A61K47/14 , A61K47/26 , A61K47/36 , A61K47/44
摘要： The invention provides pharmaceutical preparations of celecoxib in suspension, solution, and combination thereof for oral administration. Insolubility of celecoxib in water is overcome in embodiments of the invention by employing co-solvents, and liquid dosage forms having celecoxib in solution at concentrations up to 10 mg/ml are provided. Manufacturing methods for celecoxib suspensions are included in the present disclosure.

6. 发明公开

EP3246404A1 VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTS 有权
公开(公告)号：EP3246404A1
公开(公告)日：2017-11-22
申请号：EP16201637.2
申请日：2012-10-26
申请人： Danisco US Inc.
发明人： CASCAO-PEREIRA, Luis , ESTELL, David , KOLKMAN, Marc , MULDER, Harm
IPC分类号： C12N9/24 , C11D3/386 , C12N9/28
CPC分类号： C12N9/2417 , A21D8/042 , C11D3/386 , C12Y302/01001 , D06L1/14 , D06L4/40
摘要： Disclosed are compositions and methods relating to variant maltohexaose-forming alpha-amylases. The variant alpha-amylases are useful, for example, for starch liquefaction and saccharification, for cleaning starchy stains in laundry, dishwashing, and other applications, for textile processing ( e.g ., desizing), in animal feed for improving digestibility, and for baking and brewing.

7. 发明公开

EP3206498A1 METHODS FOR CONDUCTING STIMULUS-RESPONSE STUDIES WITH INDUCED PLURIPOTENT STEM CELLS DERIVED FROM PERINATAL CELLS OR TISSUES 审中-公开
标题翻译：诱导来自培养细胞或组织的诱导性多潜能干细胞刺激 - 反应研究的方法
公开(公告)号：EP3206498A1
公开(公告)日：2017-08-23
申请号：EP15851187.3
申请日：2015-10-15
申请人： Coyne IP Holdings, LLC
发明人： COYNE, Shawn T. , COYNE, Kevin P.
IPC分类号： A01N63/00 , C12N5/00 , G01N33/567
CPC分类号： G01N33/5073 , A61K35/12 , C12N5/00 , C12N5/0606 , C12N5/0696 , C12Q1/02
摘要： Methods are provided herein for conducting stimulus-response studies on iPSCs, or cells derived from iPSCs, that have been derived from perinatal cells collected from donors under null-exposome conditions. In some embodiments, multiple donors are involved. In other embodiments, the iPSCs are differentiated. The use of induced pluripotent stem cells (iPSCs) derived from cells that originate from neonates enable a scientist to largely remove the influences of age and environmental exposures, allowing a more targeted analysis of the direct interaction between a stimulus and a test subject. Furthermore, use of iPSCs derived from cells originating from multiple donors enable the scientist to obtain more precise measurements of the role of genetic differences in determining responses to a given stimulus than the use of other test materials, by eliminating the vast majority of the differential influences of age and environment among test subjects.
摘要翻译：本文提供了用于对在无效暴露条件下从供体收集的围产期细胞衍生的iPSC或源自iPSC的细胞进行刺激 - 反应研究的方法。在一些实施例中，涉及多个供体。在其他实施方案中，iPSC是有区别的。使用源自新生儿细胞的诱导性多能干细胞（iPSC）能够使科学家在很大程度上消除年龄和环境暴露的影响，从而更有针对性地分析刺激与受试者之间的直接相互作用。此外，使用源自多个供体的细胞的iPSC使得科学家能够通过消除绝大多数差异影响来获得更精确的测量遗传差异在确定对给定刺激的反应方面的作用的测量结果，而不是使用其他测试材料年龄和环境的测试科目。

8. 发明公开

EP3010518A1 VACCINIA VIRUS FOR GENE-DIRECTED ENZYME PRODRUG THERAPY 有权转让
标题翻译：牛痘病毒基因导向酶前体疗法
公开(公告)号：EP3010518A1
公开(公告)日：2016-04-27
申请号：EP14732604.5
申请日：2014-06-18
申请人： The Institute of Cancer Research: Royal Cancer Hospital
发明人： MARAIS, Richard , SPRINGER, Caroline , TOMMASINI, Serena
IPC分类号： A61K35/76 , A61K38/48 , A61K31/135 , A61P35/00
摘要： Methods of making vaccinia viruses for gene-directed prodrug therapy are disclosed and their use in the treatment of disease is provided. In particular, the anti-tumor effects of vaccinia viruses that are modified to express a prodrug-activating enzyme are disclosed.

9. 发明公开

EP3421597A1 CHRYSOSPORIUM LUCKNOWENSE PROTEIN PRODUCTION SYSTEM 有权
公开(公告)号：EP3421597A1
公开(公告)日：2019-01-02
申请号：EP18166845.0
申请日：2010-03-16
申请人： Danisco US Inc.
发明人： Punt, Peter J. , Burlingame, Richard Paul , Pynnonen, Christine M. , Olson, Phillip T. , Wery, Jan , Visser, Johannes Heinrich , Emalfarb, Mark A. , Visser, Jacob , Verdoes, Jan Cornelis
IPC分类号： C12N15/00 , C12N15/09 , C12P21/02 , C12R1/645
摘要： The present invention provides a new fungal production system comprising a fungal host strain of Chrysosporium lucknowense wherein the endogenous cellulase secretion is less than 20 % of the endogenous cellulase secretion of Chrysosporium lucknowense strain UV 18-25. Preferably, also the secretion of endogenous protease, endogenous β-glucanase and endogenous cellobiohydrolase is less than 20 % of the secretion of Chrysosporium lucknowense strain UV 18-25. Furthermore, fungal host strains are provided wherein several genes have been disrupted. According to another aspect of the invention a method for homologous and/or heterologous production of a pure protein with a purity of higher than 75 %, comprising expressing a gene encoding said protein in the strains according to the invention have been described. Furthermore, a method for production of artificial protein mixes comprising expressing a gene encoding each of said proteins in a strain according to the invention have been disclosed. Finally a method for simplified screening of strains functionally expressing a desired enzyme by application of said strains have been provided.

10. 发明公开

EP3310171A1 CHELATING BASE PRODUCT FOR USE IN WATER-BASED SYSTEM TREATMENTS AND METHOD OF MAKING BASE PRODUCT 有权转让
标题翻译：螯合用于水基系统处理的基础产品和制备基础产品的方法
公开(公告)号：EP3310171A1
公开(公告)日：2018-04-25
申请号：EP16812425.3
申请日：2016-06-16
申请人： Earth Science Laboratories
发明人： NICHOLAS, David , BOWMAN, Reid , HAMMOND, David , SINGLETON, Fred
IPC分类号： A01N59/02 , C01C1/242 , C02F1/50 , C02F5/08 , C05C3/00
CPC分类号： C02F1/683 , C02F1/50 , C02F1/505 , C02F1/68 , C02F2101/10 , C02F2103/42 , C02F2303/02 , C02F2303/04 , C05C3/00 , C05D5/00 , C05D9/00 , C05D9/02 , C05G3/0064
摘要： A base product fluid is produced by adding anhydrous liquid ammonia and a first portion of sulfuric acid to water in a process line to form a mixed fluid. The mixed fluid may be cooled and a second portion of sulfuric acid may be added to the mixed fluid to form the base product fluid. The base product fluid may include a molecular compound that is a chelating compound. The molecular compound may have the formula: ((NH4)2SO4)a.(H2SO4)b.(H2O)c.(NH4HSO4)x. In the formula, a may be between 1 and 5, b may be between 1 and 5, c may be between 1 and 5, and x may be between 1 and 10.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式